Results 91 to 100 of about 54,019 (242)
Movement Disorders Clinical Practice, EarlyView.Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider +3 more
wiley +1 more source
Response of Macroprolactinemia to Dopamine Agonists
Endocrinology Research and Practice, 2008 Macroprolactinemia, defined as hyperprolactinemia with a predominance of the big big prolactin (macroprolactin) isoform, is considered idiopathic and poorly symptomatic. Although macroprolactinemia has been considered to be a cause of apparent resistance
Gonca Tamer +3 more
doaj +2 more sources
Movement Disorders Clinical Practice, EarlyView.Abstract Background 22q11.2 deletion syndrome (22q11DS) is a multisystem genetic disorder associated with a significantly increased risk of early‐onset Parkinson's disease (EOPD). Management is challenging because psychiatric and cognitive comorbidities often limit advanced therapies such as deep brain stimulation (DBS). Cases We report 2 patients with
Valle Victor Andrés +10 more
wiley +1 more source
Metabolic effects of prolactin and the role of dopamine agonists: A review. [PDF]
Front Endocrinol (Lausanne), 2022 Kirsch P, Kunadia J, Shah S, Agrawal N.
europepmc +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Objective Examine the longitudinal relationship between caregiver strain and Parkinson's patient depression, daytime sleepiness, and treatment with dopamine agonists and antidepressants. Background Parkinson's disease (PD) is a neurodegenerative disorder, in which family caregivers play an integral role in patient care.
Sarah Holden +6 more
wiley +1 more source
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24‐h delivery of levodopa‐carbidopa prodrugs for advanced Parkinson's disease. Real‐world 1‐year European data remain limited. Objectives To characterize 1‐year changes in motor, non‐motor, autonomic, quality‐of‐life and sleep outcomes, and in concomitant therapy ...
Mario Hero +5 more
wiley +1 more source
Expanding the Phenotype of PARK‐PRKN to Spastic Paraplegia: A Report of Two Cases
Movement Disorders Clinical Practice, EarlyView.
Nicolas Geoffre +5 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background Previous studies on calcium channel blockers (CCBs) and Parkinson's disease (PD) risk reached conflicting conclusions. Objectives We examined the relationship between CCBs and PD in the E3N cohort of French women followed for 15 years (2004–2018), while taking into account the potential for reverse causation.
Emilie Moutard +9 more
wiley +1 more source
Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion
Movement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley +1 more source
Long‐Duration Response to Levodopa in the PPMI‐Cohort
Movement Disorders, EarlyView.Abstract Background Treatment of Parkinson's disease (PD) with levodopa results in a sustained reduction of symptoms. Although the plasma half‐life of levodopa is short, it elicits a lasting effect, the long‐duration levodopa response (LDR). A decrease in LDR as PD progresses has been linked to motor complications, but long‐term data on the LDR and its
Nils Schnalke +3 more
wiley +1 more source